Skip to content Skip to footer
Better biomarkers, new FDA approvals and an emerging delivery pipeline strengthen the case for Parkinson’s innovation, with AbbVie and Serina Therapeutics offering distinct investment angles. The most compelling Parkinson’s investment story does not begin with a stock chart. It begins with a…
Private-market investment is financing the next generation of AI businesses, and public-market investors may not need an invitation to Silicon Valley’s inner circle to participate. Wall Street’s next growth engine may already be under construction, financed by many willing to write enormous…